- cafead   Jul 03, 2024 at 11:33: AM
via After more than a decade with no treatment advances for chronic obstructive pulmonary disease (COPD), two have been approved by regulators on either side of the Atlantic within a week.
Wednesday, the European Medicines Agency (EMA) signed off on Regeneron and Sanofi’s anti-inflammatory blockbuster Dupixent to treat COPD, which restricts airflow from the lungs and leaves patients struggling to breathe.
article source
Wednesday, the European Medicines Agency (EMA) signed off on Regeneron and Sanofi’s anti-inflammatory blockbuster Dupixent to treat COPD, which restricts airflow from the lungs and leaves patients struggling to breathe.
article source